The estimated Net Worth of David F Hale is at least $161 Mille dollars as of 23 February 2024. Mr. Hale owns over 980 units of Biocept Inc stock worth over $12,905 and over the last 11 years he sold BIOC stock worth over $19,884. In addition, he makes $128,500 as Non-Executive Chairman of the Board at Biocept Inc.
Sign up
Mr. Hale BIOC stock SEC Form 4 insiders trading
David has made over 11 trades of the Biocept Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 980 units of BIOC stock worth $8,859 on 23 February 2024.
The largest trade he's ever made was buying 90,909 units of Biocept Inc stock on 19 October 2016 worth over $100,000. On average, David trades about 6,428 units every 107 days since 2013. As of 23 February 2024 he still owns at least 29,673 units of Biocept Inc stock.
You can see the complete history of Mr. Hale stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Hale biography
David F. Hale serves as Non-Executive Chairman of the Board of the Company. Mr. Hale was appointed as our Executive Chairman in March 2011. As of and in connection with the closing of our initial public offering on February 10, 2014, Mr. Hale now serves as non-executive Chairman. He is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences companies. He served as the Chairman of Santarus, Inc., a specialty biopharmaceutical company, since 2004 and a member of Santarus’ board since 2000, prior to its acquisition by Salix Pharmaceuticals, Ltd. in 2014. He also serves as Chairman of Conatus Pharmaceuticals, Inc. and Oncternal Therapeutics, Inc., public companies. He was previously President and CEO of CancerVax Corporation from October 1999 through its merger in May 2006 with Micromet, Inc., when he became Chairman of the combined companies. He is a co-founder and served as Chairman of Somaxon Pharmaceuticals, Inc. before its acquisition by Pernix Therapeutics Holdings, Inc., and as Chairman of SkinMedica, Inc., before its acquisition by Allergan, Inc. He also serves as Chairman of Adigica Health, Inc., Clarify Medical, Inc., MDR Aesthetics, Inc., Neurana Pharmaceuticals, Inc., Recros Medica, Inc., and Dermata Therapeutics, LLC. In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, he served as COO, President and then Chief Executive Officer, when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 until 1997 he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was later acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995, when Viagene was acquired by Chiron, Inc. He was President and CEO of Women First HealthCare, Inc.
What is the salary of David Hale?
As the Non-Executive Chairman of the Board of Biocept Inc, the total compensation of David Hale at Biocept Inc is $128,500. There are 4 executives at Biocept Inc getting paid more, with Michael Nall having the highest compensation of $1,216,060.
How old is David Hale?
David Hale is 71, he's been the Non-Executive Chairman of the Board of Biocept Inc since 2014. There are 5 older and 14 younger executives at Biocept Inc. The oldest executive at Biocept Inc is Margaret Faye Wilson, 82, who is the Lead Independent Director.
What's David Hale's mailing address?
David's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 230, , SAN DIEGO, CA, 92130.
Insiders trading at Biocept Inc
Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff e David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.
What does Biocept Inc do?
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
What does Biocept Inc's logo look like?
Complete history of Mr. Hale stock trades at Biocept Inc, Conatus Pharmaceuticals e Oncternal Therapeutics
Biocept Inc executives and stock owners
Biocept Inc executives and other stock owners filed with the SEC include:
-
Michael Nall,
President, Chief Executive Officer, Director -
Timothy Kennedy,
Chief Financial Officer, Senior Vice President - Operations, Corporate Secretary -
Michael Terry,
Sr. VP of Corp. Devel. -
Lyle Arnold,
Senior Vice President - Research & Development, Chief Scientific Officer -
David Hale,
Non-Executive Chairman of the Board -
Samuel D. Riccitelli,
Interim Pres & CEO and Independent Chairman -
Margaret Faye Wilson,
Lead Independent Director -
Ivor Royston,
Independent Director -
Bruce Huebner,
Independent Director -
Bruce Gerhardt,
Independent Director -
Marsha Chandler,
Independent Director -
Samuel Riccitelli,
Director -
Michael Terry,
Senior Vice President - Corporate Development -
Cory Dunn,
Senior Vice President of Commercial Operations -
Antonio Paternostro,
VP of Sales -
Dr. Philippe J. Marchand Ph.D.,
Chief Operating Officer -
Dr. Michael C. Dugan M.D.,
Sr. VP, Chief Medical Officer & Medical Director -
Dr. Veena M. Singh,
Sr. Medical Director -
David S. Moskowitz R.Ph., MBA,
VP of Strategy & Corp. Communications -
Darrell Taylor Esq.,
Sr. VP, Chief Legal Officer & Chief Compliance Officer -
Dr. Lyle J. Arnold Ph.D.,
Chief Scientist & Member of Scientific Advisory Board -
Pavel Tsinberg,
Director of Technology Devel. -
Antonino Morales,
Interim CFO & Director -
Dr. Soon Kap Hahn Ph.D.,
Founder -
Quyen Thi Dao Haddock,
Director -
Bridge Lb Healthcare Master...,
-
Edward A. Neff,
Director -
Veena Singh,
Sr VP & Sr Med Director -
Claire Reiss,
10% owner -
Linda M Rubinstein,
Director -
Raaj Trivedi,
VP, COMMERCIAL OPERATIONS -
Mark G Foletta,
Interim CFO -
Philippe Marchand,
Chief Operations Officer -
William G Kachioff,
SVP, CFO AND SECRETARY -
Farideh Z. Bischoff,
VICE PRESIDENT -
Darrell Taylor,
See remarks -
Michael C Dugan,
Chief Med Off & Med. Director -
Antonino Morales,
Interim CFO